Extended Data Fig. 2: Therapeutic effect of Neo-2/15 on melanoma. | Nature

Extended Data Fig. 2: Therapeutic effect of Neo-2/15 on melanoma.

From: De novo design of potent and selective mimics of IL-2 and IL-15

Extended Data Fig. 2

Survival curves (top) and tumour growth curves (bottom) for C57BL/6 mice that were inoculated with B16 tumours (as in Fig. 4a) and treated with low (1 μg per mouse per day) or high (10 μg per mouse per day) doses of Neo-2/15. a, Starting on day 1, mice (n = 5 per group) were treated daily with intraperitoneal injection of single agent Neo-2/15 at 1 μg per mouse or equimolar mouse IL-2 (left), or the same treatments in combination with a twice-weekly treatment with TA99 (started on day 5) (right). Mice were euthanized when tumour size reached 2,000 mm3. Tumour growth curves show data only for surviving mice and stop if the number of mice in a group fell below 50% of the initial number. The experiments were performed twice with similar results. b, Similar to a, but starting on day 4. Mice (n = 5 per group) were treated daily with intraperitoneal injection of single agent Neo-2/15 at 10 μg per mouse or equimolar mouse IL-2 (left), or the same treatments in combination with a twice-weekly treatment with TA99 (started on day 4) (right). Mice were euthanized when tumour size reached 1,000 mm3. The therapeutic effect of Neo-2/15 is dose-dependent (higher doses have a stronger effect) and is potentiated in the presence of the antibody TA99. Tumour growth curves show data only for surviving mice and stop if the number of mice in a group fell below 50% of the initial number. The experiments were performed twice with similar results. c, C57BL/6 mice were immunized with 500 μg KO Neo-2/15 in complete Freund’s adjuvant and boosted on days 7 and 15 with 500 μg KO Neo-2/15 in incomplete Freund’s adjuvant. Reactivity against KO Neo-2/15 and native Neo-2/15, as well as cross-reactivity with mouse IL-2 were determined by incubation of serum (diluted 1:1,000 in PBS) with plate-bound KO Neo-2/15, Neo-2/15 or mouse IL-2 as indicated. Serum binding was detected using an anti-mouse secondary antibody conjugated to HRP followed by incubation with TMB. Data are reported as optical density at 450 nm. Top, naive mouse serum; bottom, immunized mouse serum. The experiments were performed once. In all the growth curves, data are mean ± s.e.m. Results were analysed by one-way ANOVA (95% confidence interval), except for survival curves that were assessed using the Mantel–Cox test (95% confidence interval).